S-Docs Unveils Next-Level Experience To Redefine Operational Efficiency
12.9.2023 19:35:00 EEST | Business Wire | Press release
S-Docs, a market leader in document automation and e-signature, today announced three major upgrades to its flagship document automation solution. Set to be released in separate installments, these updates include a consolidated document creation workflow, a best-in class template editor experience, and an AI-driven document assistant.
“S-Docs is innovating to redefine productivity for our customers,” said Brian Stimpfl, Chief Executive Officer at S-Docs. “This new product evolution will dramatically streamline our users' workflows to maximize operational efficiency and elevate the customer experience.”
The first update marks the largest customer experience overhaul in S-Docs history. Anticipated for release this month, this feature empowers users to generate, view, and distribute documents from their existing work interface. “What used to require multiple steps is now one fluid operation,” said Anand Narasimhan, Chief Technology Officer at S-Docs. “This transformation will mark a major shift in our customers’ approach to document automation and reinforces our dedication to seamless customer experiences.”
In addition, S-Docs is launching an entirely new template editor in early 2024. This redesigned, intuitive interface will streamline and democratize template creation across all levels and roles within an organization. “Our aim is to simplify the document lifecycle from start to finish,” stated Anand Narasimhan. “The new editor will allow any user to construct dynamic documents that are always connected to the people, processes, and data that go into them.”
Finally, S-Docs is introducing generative AI to its products in 2024. This innovation will enable customers with a document copilot, providing dynamic content generation and document analysis capabilities. “By integrating AI, we’re enabling both end users and administrators to achieve in seconds what used to take hours,” Anand Narasimhan explained. “With integrity at the heart of S-Docs’ core values, we’re developing our AI solutions within a zero-trust security framework to put data privacy first as we pave the way for a new era in document automation.”
“These updates represent a significant milestone in S-Docs’ vision to revolutionize the way organizations create, manage, and share information,” said Brian Stimpfl.
As businesses look to stay ahead in a rapidly changing landscape, S-Docs’ product enhancements are poised to set new benchmarks for operational efficiency.
To learn more about S-Docs, please visit www.sdocs.com.
About S-Docs:
S-Docs is a document automation and e-signature solution for Salesforce. Companies of all sizes in every industry rely on S-Docs to eliminate manual work and simplify complex processes, resulting in increased productivity, enhanced customer experiences, and accelerated business success.
The company is privately held with headquarters in New York and offices in Ann Arbor. Learn more at sdocs.com and follow us on LinkedIn.
Use of the term Salesforce are the trademarks of Salesforce.com, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912664296/en/
Contact information
Dyana Quinlivan
dquinlivan@sdocs.com
(303)263-6741
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom